Total: 2075

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. Commercial arrangement There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...

    Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing. Guidance development process Early value assessment (EVA) guidance rapidly provides recommendations on promising health technologies that have the potential to address national...

    Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

    Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults....

    Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)

    NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission....

    Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

    People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and bendamustine. The clinical evidence is from a small study that did not directly compare tafasitamab plus lenalidomide with any other trea...

    Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations

    Crit Care Med; 15 (5), 2023
    To develop evidence-based recommendations for clinicians caring for adults with acute liver failure (ALF) or acute on chronic liver failure (ACLF) in the ICU. The guideline panel comprised 27 members with expertise in aspects of care of the critically ill patient with liver failure or methodology. We adh...

    Clinical Guidelines for Diagnosis and Management of Juvenile Polyposis Syndrome in Children and Adults―Secondary Publication

    J Anus Rectum Colon; 7 (2), 2023
    Juvenile polyposis syndrome (JPS) is a rare disease characterized by multiple hamartomatous polyps within the gastrointestinal tract. SMAD4 or BMPR1A is known as a causative gene of JPS. Approximately 75% of newly diagnosed cases have an autosomal-dominantly inherited condition, whereas 25% are sporadic ...